CNTX Key Statistics, Chart & Performance
The current stock price of CNTX is 1.0746 USD. In the past month the price decreased by -13.49%. In the past year, price decreased by -21.58%.
CNTX Latest News, Press Relases and Analysis
CNTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.87 | 996.22B | ||
| JNJ | JOHNSON & JOHNSON | 19.62 | 490.46B | ||
| MRK | MERCK & CO. INC. | 11.46 | 252.20B | ||
| PFE | PFIZER INC | 7.85 | 142.82B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.3 | 97.43B | ||
| ZTS | ZOETIS INC | 19.02 | 53.43B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.37 | 22.46B | ||
| VTRS | VIATRIS INC | 4.51 | 12.24B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.6 | 11.26B | ||
| CORT | CORCEPT THERAPEUTICS INC | 89.14 | 8.25B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.47B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.86B |
Related stock screener links
About CNTX
Company Profile
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 12 full-time employees. The company went IPO on 2021-10-20. The company is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.
Company Info
CONTEXT THERAPEUTICS INC
2001 Market Street, Suite 3915 Unit #15
PHILADELPHIA PENNSYLVANIA US
Employees: 12
Phone: 12672257416
CONTEXT THERAPEUTICS INC / CNTX FAQ
Can you describe the business of CONTEXT THERAPEUTICS INC?
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 12 full-time employees. The company went IPO on 2021-10-20. The company is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.
What is the current price of CNTX stock?
The current stock price of CNTX is 1.0746 USD. The price decreased by -1.41% in the last trading session.
Does CONTEXT THERAPEUTICS INC pay dividends?
CNTX does not pay a dividend.
How is the ChartMill rating for CONTEXT THERAPEUTICS INC?
CNTX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of CONTEXT THERAPEUTICS INC (CNTX)?
CONTEXT THERAPEUTICS INC (CNTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.28).
What is the market capitalization of CNTX stock?
CONTEXT THERAPEUTICS INC (CNTX) has a market capitalization of 98.73M USD. This makes CNTX a Micro Cap stock.
What is the Short Interest ratio of CONTEXT THERAPEUTICS INC (CNTX) stock?
The outstanding short interest for CONTEXT THERAPEUTICS INC (CNTX) is 0.96% of its float.
CNTX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CNTX. When comparing the yearly performance of all stocks, CNTX turns out to be only a medium performer in the overall market: it outperformed 51.59% of all stocks.
CNTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CNTX. CNTX has a great financial health rating, but its profitability evaluates not so good.
CNTX Financial Highlights
Over the last trailing twelve months CNTX reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS increased by 69.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.37% | ||
| ROE | -36.13% | ||
| Debt/Equity | 0 |
CNTX Forecast & Estimates
14 analysts have analysed CNTX and the average price target is 5.44 USD. This implies a price increase of 406.23% is expected in the next year compared to the current price of 1.0746.